Drug intelligence / Profile preview

N6-R-phenylisopropyladenosine

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal, Intravenous, Subcutaneous

Overview

N6-R-phenylisopropyladenosine (R-PIA) is a selective adenosine receptor agonist, primarily acting on adenosine A1 receptors, widely used in neuropharmacological research. It is known for inducing effects such as hypoactivity, hypothermia, muscle relaxation, and antinociception in animal models. R-PIA can also stimulate feeding behavior in rats at times typically associated with low food intake, via a mechanism that is independent of canonical adenosine A1 or A2 receptor pathways[3]. It is used extensively as a pharmacological tool to study adenosine receptor-mediated mechanisms.

Other names: N6-(R)-phenylisopropyladenosine

Targets

ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on N6-R-phenylisopropyladenosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N6-R-phenylisopropyladenosine.

Explore the full profile